Immune checkpoint inhibitors have revolutionised care for patients with advanced melanoma, with around half of patients with unresectable metastatic melanoma living to five years...

In this presentation given at the Yale School of Medicine Dermatology Grand Rounds, world-leading melanoma pathologist, Prof Richard Scolyer AO, discusses: • MIA’s goals...

The field of melanoma has experienced a paradigm shift in recent years, with advancements in both diagnosis and management driving improved patient outcomes. Through...

‘To shave or not to shave, that is the question.’ In this engaging debate, Dermatologist A/Prof Victoria Mar and Surgeon Prof Michael Henderson present...

During this presentation, leading clinicians discuss the biology, assessment and treatment of non-melanoma skin cancers, including Merkel cell carcinoma, squamous cell carcinoma (SCC) and...

‘To shave or not to shave, that is the question.’ In this engaging debate, Dermatologist A/Prof Victoria Mar and Surgeon Prof Michael Henderson present...

Managing in-transit melanoma can be challenging, and it presents and progresses as a heterogeneous disease. Multidisciplinary care is recommended for this complex disease to...

In this interview from Oncology News Australia, MIA’s Prof Georgina Long AO speaks with Dr Craig Underhill on a wide range of developments in...